A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Astellas

Status and phase

Completed

Phase 3

Conditions

Chronic Kidney Disease

Treatments

Drug: roxadustat

Study type

Interventional

Funder types

Industry

Identifiers

NCT02964936

1517-CL-0314

Details and patient eligibility

About

The objective of this study is to evaluate the efficacy and the safety when ASP1517 is intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis chronic kidney disease patients with anemia.

Enrollment

100 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects who were diagnosed with non-dialysis chronic kidney disease (CKD) and who are considered not to require renal replacement therapy during the study period
Mean of the subject's two most recent Hb values before randomization during the Screening Period must be <10.5 g/dL with an absolute difference ≤1.3 g/dL between the two values
Either transferrin saturation ≥ 5% or serum ferritin ≥ 30 ng/mL
Female subject must either:

Be of non-childbearing potential:

post-menopausal prior to pre-screening, or
documented surgically sterile Or, if of childbearing potential,
Agree not to try to become pregnant during the study after informed consent acquisition and for 28 days after the final study drug administration
And have a negative urine pregnancy test at pre-screening
And, if heterosexually active, agree to consistently use two forms of highly effective birth control (at least one of which must be a barrier method) starting at pre-screening and throughout the study period and for 28 days after the final study drug administration.
Female subject must agree not to breastfeed starting at pre-screening and throughout the study period, and for 28 days after the final study drug administration.
Female subject must not donate ova starting at pre-screening and throughout the study period, and for 28 days after the final study drug administration.
Male subject and their female spouse/partners who are of childbearing potential must be using two forms of highly effective birth control (at least one of which must be a barrier method) starting at pre-screening and continue throughout the study period, and for 12 weeks after the final study drug administration
Male subject must not donate sperm starting at pre-screening and throughout the study period, and for 12 weeks after the final study drug administration

Exclusion criteria

Concurrent retinal neovascular lesion requiring treatment and macular edema requiring treatment
Concurrent autoimmune disease with inflammation that could impact erythropoiesis
History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent gastroparesis
Uncontrolled hypertension
Concurrent congestive heart failure (NYHA Class III or higher)
History of hospitalization for treatment of stroke, myocardial infarction, or pulmonary embolism within 12 weeks before the pre-screening assessment
Positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) antibody at the pre-screening assessment, or positive for human immunodeficiency virus (HIV) in a past test
Concurrent other form of anemia than renal anemia
Having received treatment with ESA, protein anabolic hormone, testosterone enanthate, or mepitiostane within 6 weeks before the pre-screening assessment
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) or total bilirubin that is greater than the criteria, or previous or concurrent another serious liver disease at pre-screening assessment
Previous or current malignant tumor (no recurrence for at least 5 years is eligible.)
Having undergone red blood transfusion and/or a surgical procedure considered to promote anemia within 4 weeks before the pre-screening assessment
Having undergone a kidney transplantation
History of serious drug allergy including anaphylactic shock
Having a previous history of treatment with ASP1517
Participation in another clinical study or post-marketing clinical study (including that of a medical device) within 12 weeks before informed consent acquisition